Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Orthocell's Remplir nerve wrap hit its highest U.S. monthly sales since launch in October 2026, signaling growing market traction.
Australian medical device maker Orthocell Ltd recorded its strongest month of U.S. sales for its Remplir nerve wrap since the product's commercial launch, the company disclosed. The milestone came in October 2026, when 92 units of the FDA-cleared device were sold in the American market.
Remplir is a collagen-based nerve wrap engineered to support the repair and protection of peripheral nerves following injury or surgical intervention. Designed and manufactured in Australia, the device has received FDA clearance and is being positioned as a category leader in key international markets.
Read more Global Vote Opens to Crown 7 Wonders of Future Cities →
The October sales figure represents a meaningful commercial benchmark for Orthocell as it works to expand its footprint in the competitive U.S. medical device sector. Peripheral nerve repair is a growing clinical focus area, and collagen-based wraps are increasingly being adopted by surgeons seeking alternatives to traditional repair techniques.
Orthocell's progress in the U.S. market underscores broader momentum for Australian-developed medical technologies gaining regulatory and commercial acceptance abroad. The company has not disclosed specific revenue figures tied to the October unit volume, but the sales milestone suggests accelerating physician adoption of Remplir since its stateside introduction.
Continue reading at All Financial Services & Investing.
